Allergy Therapeutics, who are based in Worthing and are specialists in allergy vaccines, have received approval for a Phase II clinical trial, which aims to cure grass pollen-induced allergies.
PQ is a unique, ultra-short course injected product, with the potential to cure allergic rhinitis, caused by grass pollen.
The product, if successful, is anticipated to see the U.S as its main market – estimated by the Group to be worth $2bn with potential peak sales of $300m per annum.
It would also be the first registered subcutaneous immunotherapy product in the USA.
The trial is expected to start ‘imminently’ and will take place in Germany, Poland and Austria. It will involve approximately 440 patients.
Manuel Llobet, Chief Executive Officer of Allergy Therapeutics, commented: “This revised Phase II trial will prepare the ground for entry in to the high value US market in which PQ Grass has the potential to become a convenient, best in class, ultra-short course subcutaneous immunotherapy.
“We look forward to reporting headline data next year as we advance this product.”